Related Experiment Video
Updated: Oct 22, 2025

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
Published on: March 29, 2024
β-elemene blocks lipid-induced inflammatory pathways via PPARβ activation in heart failure
Mingyan Shao1, Mingmin Wang2, Lin Ma1
1Beijing Key Laboratory of Traditional Chinese Medicine Syndrome and Formula, School of Life Science, Beijing University of Chinese Medicine, Beijing 100029, China.
Abstract:
This study aims to investigate the effects of β-elemene on a mouse model of heart failure (HF) and to elucidate the underlying mechanisms in vitro approaches. In this study, left anterior descending (LAD)-induced HF mouse model and oxygen-glucose deprivation/recovery (OGD/R)-induced H9C2 model were leveraged to assess the therapeutic effects of β-elemene. Histological examination, western blot and quantitative real-time PCR analysis (RT-qPCR) and immunofluorescence staining was utilized to elucidate mechanism of β-elemene in lipid-induced inflammation. Results showed that β-elemene improved heart function in HF mice evidenced by the increase of cardiac ejection fraction (EF) and fractional shortening (FS) values. Furthermore, β-elemene administration rescued ventricular dilation, lipid accumulation, and inflammatory infiltration in arginal areas of mice myocardial infarction. At transcription level, β-elemene augmented the mRNA expression of fatty acid oxidation-associated genes, such as peroxisome proliferator-activated receptor-β (PPARβ). In vitro, treatment of β-elemene increased carnitine palmitoyltransferase 1A (CPT1A) and sirtuin 3 (SIRT3). Hallmarks of inflammation including the nuclear translocation of nuclear factor κB (NF-κB) and the degradation of inhibitory κBα (IκBα) were significantly suppressed. Consistently, we observed down-regulation of interleukin-6 (IL-6) and pro-inflammatory cytokines (such as TNFα) in β-elemene treated H9C2 cells. Finally, molecular docking model predicted an interaction between β-elemene and PPARβ protein. Furthermore, β-elemene increased the expression of PPARβ, which was validated by antagonist of PPARβ and siRNA for PPARβ.
Related Concept Videos
Heart Failure Drugs: β-Blockers
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Adrenergic Antagonists: ɑ and β-Receptor Blockers
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
Antihypertensive Drugs: Action of β1 Blockers
Heart Failure II: Pathophysiology

